News · 26 weeks49-27%
2026-04-192026-10-11
Mix2990d
- SEC Filings11(38%)
- Other10(34%)
- Insider6(21%)
- Analyst2(7%)
Latest news
25 items- SECSEC Form 8-K filed by Quoin Pharmaceuticals Ltd.8-K - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union – Designation Represents Eighth Important Regulatory Milestone for QRX003 – QRX003 has also been granted Pediatric Rare Disease Designation and Fast Track Designation for Peeling Skin Syndrome from US Food and Drug Administration – In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation in US, Europe and Japan as well as Pediatric Rare Disease and Fast Track Designations in the US ASHBURN, Va.,
- ANALYSTBTIG Research initiated coverage on Quoin Pharmaceuticals with a new price targetBTIG Research initiated coverage of Quoin Pharmaceuticals with a rating of Buy and set a new price target of $14.00
- PRQuoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and TherapyPeer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton SyndromeCase Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled "An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report" has been accepted for publication in a forthcoming issue of Dermatology and Therapy.
- SECSEC Form DEF 14A filed by Quoin Pharmaceuticals Ltd.DEF 14A - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- SECSEC Form EFFECT filed by Quoin Pharmaceuticals Ltd.EFFECT - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- SECSEC Form 424B3 filed by Quoin Pharmaceuticals Ltd.424B3 - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- ANALYSTLake Street initiated coverage on Quoin Pharmaceuticals with a new price targetLake Street initiated coverage of Quoin Pharmaceuticals with a rating of Buy and set a new price target of $20.00
- SECSEC Form PRE 14A filed by Quoin Pharmaceuticals Ltd.PRE 14A - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- SECQuoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need – Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome – Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe – Peeling Skin Syndrome Currently Has No Approved Treatment ASHBURN, Va., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNR
- SECSEC Form S-3 filed by Quoin Pharmaceuticals Ltd.S-3 - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- SECSEC Form D filed by Quoin Pharmaceuticals Ltd.D - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- SECQuoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Quoin Pharmaceuticals Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICUASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the latest episode in its NETHERTON NOW video series. This episode is about Aminah and is told by her adoptive mother, Laura Wright-Sexton, MD, a board-certified pediatric critical care physician who first met Aminah as a critically ill 10-month-old Netherton Syndrome patient in the pediatric intensive care unit where she practiced. Seven months later, Aminah joined Laura’s family through adoption. Aminah was admitted to the hospital where Laura worked
- PRCORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin SyndromeSecond Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan disea
- PRQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin SyndromeSecond Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan disea
- INSIDERChief Operating Officer Carter Denise P. bought $99,991 worth of ADSs (20,490 units at $4.88), increasing direct ownership by 119% to 37,709 units (SEC Form 4)4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- INSIDERChief Executive Officer Myers Michael bought $99,991 worth of ADSs (20,490 units at $4.88), increasing direct ownership by 119% to 37,713 units (SEC Form 4)4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- INSIDERChief Financial Officer Lawlor Sally Bridget bought $49,991 worth of ADSs (10,244 units at $4.88), increasing direct ownership by 2,328% to 10,684 units (SEC Form 4)4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- INSIDERDirector Culverwell Anthony James bought $29,992 worth of ADSs (6,146 units at $4.88), increasing direct ownership by 18% to 40,364 units (SEC Form 4)4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- INSIDERDirector Langer Dennis was granted 34,534 units of ADSs, increasing direct ownership by 159% to 56,243 units (SEC Form 4)4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- INSIDERDirector Culverwell Anthony James was granted 31,352 units of ADSs, increasing direct ownership by 1,094% to 34,218 units (SEC Form 4)4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- SECQuoin Pharmaceuticals Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton SyndromeInterim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) With Statistical Significance versus the Pre-Specified Alpha of 0.0215Key Secondary Endpoint of Global Impression of Change Also Achieved Statistical Significance at Week 12 (p=0.0070) Versus the Pre-Specified Alpha of 0.0215 All Three Participants with Moderate-Severe Pruritus (Itch) at Baseline Achieved a Clinically Meaningful Outcome of at Least a 3-Grade Improvement After 12 Weeks of T
QNRX FAQ
7 questionsWhat does Quoin Pharmaceuticals Ltd. do?
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.Where does QNRX stock trade?
Quoin Pharmaceuticals Ltd. (QNRX) is listed on NASDAQ.What sector and industry is QNRX in?
Quoin Pharmaceuticals Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.When did Quoin Pharmaceuticals Ltd. go public?
Quoin Pharmaceuticals Ltd. (QNRX) completed its IPO in 2016.What are analysts saying about QNRX?
Quoin Pharmaceuticals Ltd. has had 2 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1400.00 price target on 2026-10-12. Recent price targets range from $1400.00 to $2000.00.What companies are similar to QNRX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare QNRX side-by-side with any of them on Quantisnow.How can I track QNRX on Quantisnow?
Quantisnow aggregates Quoin Pharmaceuticals Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QNRX to receive live email and push alerts on every new disclosure.